Skip to content

GRAIL, Inc. GRAL Price / sales

Price / sales at other companies

Abbott logo
AbbottABT
-1.5×
Guardant Health logo
Guardant HealthGH
11.2×+4.4×
Natera, Inc. logo
Natera, Inc.NTRA
11.3×+0.9×
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
5.9×-4.4×
Immunome logo
ImmunomeIMNM
616.2×+563×
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
7.2×+1.4×

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Calculated from GRAIL, Inc.’s reported figures.

Based on the most recent quarter.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s price / sales?
GRAIL, Inc. (GRAL) reported price / sales of 13.6× in Q1 2026.
How has GRAIL, Inc.'s price / sales changed year-over-year?
GRAIL, Inc.'s price / sales increased by 105.0% year-over-year, from 6.6× to 13.6×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.